Genmab — November 2017
-
Synes også salgstal er ok - og fedt med indsendelse af registeringsansøgningerne. Men med en relativ svag vækst i USA og en 1. linie godkendelse med en kombi der ikke er stor i USA, så er jeg lidt bekymret for væksten i USA i 2018 set i forhold til analytikernes forventninger.
-
hvor villige er forsikringsselskaberne til at betale til off label?
-
Lidt vildt - glæder mig til Genmab når det niveau: Celgene Corporation (NASDAQ:CELG) today announced that data from 282 abstracts, including more than 60 oral presentations, evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 59th American Society of Hematology Annual Meeting between Dec. 9-12 in Atlanta, GA
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
